InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
InflaRx reported pre-clinical data showing izicopan demonstrated minimal reactive metabolite formation in human liver microsomes, suggesting a lower bioactivation risk compared to the marketed drug avacopan. In the head-to-head in vitro study, izicopan showed lower levels of thiol adducts than avacopan, with differences exceeding 100-fold at early time points, supporting a differentiated profile for the oral C5aR1 inhibitor.
Key figures
- Phase
- 2a
- C5a blockade
- ≥90%
- Incubation time
- 0–40 minutes
- Single dose range
- 3 mg to 240 mg
- Assay concentration
- 10 µM
- Multiple dose range
- 30 mg once per day to 90 mg twice per day for 14 days
- Reactive conjugate difference
- >100-fold at 5 and 10 minutes
- Reactive conjugate difference late
- ~10-fold at 20 and 40 minutes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.